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Abstract
Ectopic gastric mucosa (EGM) is considered to be a congenital
condition. Rare cases of adenocarcinoma have been described. There
are no data justifying regular biopsies or follow-up. Cyclooxygenase-
2 (COX-2) is a protein involved in gastrointestinal tumor develop-
ment by inhibiting apoptosis and regulating angiogenesis. The aim of
this prospective study was to evaluate COX-2 expression in EGM and
compare it with normal tissue and Barrett’s esophagus. We evaluated
1327 patients. Biopsies were taken from the inlet patch for histologi-
cal evaluation and from the gastric antrum to assess Helicobacter
pylori infection. Biopsies taken from normal esophageal, gastric
antrum and body mucosa and Barrett’s esophagus were retrieved from
a tissue bank. EGM biopsies were evaluated with respect to type of
epithelium, presence of H. pylori, and inflammation. COX-2 was
detected by immunohistochemistry using the avidin-biotin complex.
EGM islets were found in 14 patients (1.1%). Histological examina-
tion revealed fundic type epithelium in 58.3% of cases, H. pylori was
present in 50% and chronic inflammation in 66.7%. Expression of
COX-2 was negative in normal distal esophagus, normal gastric
antrum and normal gastric body specimens (10 each). In contrast,
EGM presented over-expression of COX-2 in 41.7% of cases and
Barrett’s esophagus in 90% of cases (P = 0.04 and 0.03, respectively).
COX-2 immunoexpression in EGM was not related to gender, age,
epithelium type, presence of inflammation or intestinal metaplasia, H.
pylori infection, or any endoscopic finding. Our results demonstrate
up-regulation of COX-2 in EGM, suggesting a possible malignant
potential of this so-called harmless mucosa.
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Introduction
Ectopic gastric mucosa (EGM) is an asymp-
tomatic anomaly found in the cervical esopha-
gus, also designated inlet patch. Macroscopi-
cally, the patch is characterized by reddish or
salmon-red mucosa with a velvety appear-
ance. It presents as either a single or multiple
patches localized just below the upper esoph-
ageal sphincter. Microscopically, the patch
can be lined with fundic or gastric body type
glands (1-3). The prevalence of EGM ranges
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from 0.1 to 4.9% in most series, reaching
10% in a prospective study (1-3). The pres-
ence of Helicobacter pylori has been re-
ported in 20 to 56.5% of cases (1-4).
The most accepted pathogenic theory
considers EGM to be a congenital malfor-
mation. According to this theory, EGM rep-
resents the remnants of the columnar epithe-
lium, secondary to a failure of the bidirec-
tional replacement of the esophageal colum-
nar epithelium by squamous mucosa, which
starts in the mid-esophagus during the de-
scending of the stomach in the fifth month of
pregnancy (2).
There is no clear association between
EGM and Barrett’s esophagus, with contra-
dictory published data. Some investigators
believe that there is a possible link between
these two entities (5,6). On the other hand,
some immunohistochemical studies have not
confirmed this hypothesis (7).
EGM islets are generally assumed to be
incidental findings, with no biopsies being
routinely obtained and with patients not be-
ing referred to any surveillance program.
Although rare, at least 23 cases of adenocar-
cinoma have been reported in the EGM (8-
10).
The cyclooxygenase (COX) enzyme cata-
lyzes the conversion of arachidonic acid to
prostaglandins (11). Two COX isoforms have
been identified in humans, COX-1 and COX-
2. COX-1 is a constitutively expressed en-
zyme, present in most tissues including the
gastrointestinal tract, considered to be a
housekeeping gene involved in general cell
functions. COX-2 is an inducible enzyme
usually undetectable in most tissues, up-
regulated in response to various stimuli, in-
cluding growth factors, tumor promoters and
cytokines (11-13).
Over-expression of COX-2 has been
shown to have numerous effects on cells,
such as increased cell proliferation, decreased
apoptosis rate, stimulation of angiogenesis,
and increased invasive and metastatic po-
tential (13-18). Recent studies have demon-
strated over-expression of COX-2 in Barrett’s
epithelium and associated adenocarcinoma
(14,19).
Furthermore, treatment with selective
COX-2 inhibitors has been shown to reduce
damage induced by acid and pepsin in the
esophageal mucosa of rabbits and the inci-
dence of tumors in an animal model of esoph-
ageal adenocarcinoma, to decrease prolif-
eration and to induce apoptosis in both Bar-
rett’s epithelium and adenocarcinoma (14).
In the present study, we compared COX-
2 expression in biopsy specimens of hetero-
topic gastric mucosa, normal esophageal,
gastric antrum and body mucosa, and Bar-
rett’s esophagus.
Material and Methods
The study was approved by our Institu-
tional Human Research Review Committee.
Consecutive patients referred for upper gas-
trointestinal endoscopy between August 2001
and May 2002 gave written informed con-
sent and were enrolled in the study. Patients
referred for emergency procedures were ex-
cluded.
Endoscopic examination
Upper endoscopy was performed after
sedation with midazolam, meperidine or di-
azepam. All patients were prospectively as-
sessed for the presence of EGM. Its macro-
scopic characteristics were documented as
well as other endoscopic findings. Biopsies
were obtained from the heterotopic mucosa.
A biopsy from the gastric antrum was also
taken in these patients to determine H. pylori
infection by the rapid urease test (20).
Biopsy specimens obtained from the
EGM were submitted to histological evalua-
tion and to COX-2 determination by immu-
nohistochemistry. Forty biopsy samples, in-
cluding 10 from normal distal esophagus, 10
from normal gastric antrum, 10 from normal
gastric body, and 10 from confirmed Barrett’s
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esophagus (specialized intestinal epithelium
and goblet cells) without dysplasia were also
evaluated for the immunohistochemical ex-
pression of COX-2. These samples were
retrieved from our tissue bank and matched
to our EGM population for sex and age.
Histopathological examination
Biopsies were fixed in formaldehyde and
embedded in paraffin and sections were
stained with hematoxylin and eosin and
modified Giemsa. Heterotopic gastric epi-
thelium was classified as fundic, antral or
mixed type. The presence of H. pylori was
determined using the Giemsa stain.
Immunohistochemistry
Immunohistochemical studies were per-
formed on formalin-fixed paraffin-embed-
ded sections of all samples by the avidin-
biotin peroxidase complex method.
Briefly, deparaffinized and rehydrated
sections, pretreated by microwave antigen
retrieval, were sequentially incubated with
mouse anti-human COX-2 monoclonal anti-
body (Dako, Glostrup, Denmark) diluted 100
times with 1% swine serum in phosphate-
buffered saline. The secondary antibody was
biotinylated anti-mouse immunoglobulin
(Dako). Finally, the sections were incubated
with the avidin-biotin peroxidase complex
(Dako). Color was developed using 3,3'-
diaminobenzide (Sigma, St. Louis, MO, USA
- DS637) and sections were then counter-
stained with hematoxylin, dehydrated and
mounted with permount. An esophageal ad-
enocarcinoma specimen, previously shown
to have strong COX-2 expression, was used
as a positive control.
Evaluation of immunohistochemical staining
COX-2 immunohistochemical expression
was reported according to a previously pub-
lished score system (21). Staining intensity
was graded as weak, 1, moderate, 2, or strong,
3. The stained area was classified as follows:
<10% of all cells stained in the cytoplasm as
viewed by microscopy, 0; 10 to 40%, 1; 40
to 70%, 2; >70%, 3. An average immunore-
active score was calculated by multiplying
the staining intensity by the area of staining.
A total score of 3 or more was defined as
positive expression and a score of less than 3
as negative.
Statistical analysis
Data are reported as means + SD and as a
box-plot graph. Comparison between groups
was performed by the Student t-test and
Fischer exact test for both continuous and
categorical data (R 2.2.1 statistical software).
The level of significance was set at P < 0.05.
Results
Demographic characteristics of patients with
ectopic gastric mucosa
During the study period, 1327 patients
were evaluated and EGM was encountered
in 14 (1.1%), 8 of them men, with a median
age of 47.4 years (range: 22 to 84 years).
Only 2/14 patients (14.2%) with patches
reported upper esophageal or laryngopha-
ryngeal symptoms (burning in the throat and
hoarseness).
Endoscopic characteristics of ectopic gastric
mucosa
Most patients (10/14, 71.4%) presented
only one EGM patch ranging in size from 2
to 20 mm (mean size: 6.5 mm). The surface
was smooth, regular and velvety in all cases
(Figure 1).
Other endoscopic findings detected in
these patients were: gastritis (8/14), duode-
nal ulcer (4/14), peptic esophagitis (3/14),
hiatal hernia (2/14), and portal hypertension
(1/14). No Barrett’s esophagus was found.
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The ectopic patch group did not present
more endoscopic findings suggestive of gas-
troesophageal reflux disease (hiatal hernia,
esophagitis and Barrett’s esophagus) than
the patients without EGM patches (P = 0.16).
Histological characteristics of ectopic gastric
mucosa
Because of technical problems, histo-
logical and immunohistochemical examina-
tions were performed in only 12 cases. The
histological results are summarized in Table 1.
Hematoxylin and eosin staining revealed
fundic type mucosa in 7/12 cases (58.3%)
and mixed (antral/fundic) in 5/12 (41.7%).
Mild chronic inflammation was found in 5/
12 patients (41.7%), inactive chronic in-
flammation in 3/12 (25%), and absence of
inflammation in 4/12 (33.3%).
H. pylori was identified in the ectopic
epithelium in half the cases (6/12). All pa-
tients colonized with the bacteria in the inlet
patch were also infected in the antrum, as
confirmed by a positive rapid urease test.
Of 9 patients with confirmed antral H.
pylori infection, 6 (66.7%) also had H. pylo-
ri in the patch. No correlation between H.
pylori infection and the type of epithelium,
the presence of intestinal metaplasia, or an-
tral colonization could be established (Table
2). However, the presence of chronic in-
flammation was significantly correlated with
H. pylori infection in the EGM (P = 0.01),
according to the chi-square test.
Two cases of intestinal metaplasia in the
ectopic mucosa were identified and con-
firmed by the presence of specialized intes-
tinal epithelium and goblet cells.
Immunohistochemistry
As shown in Figure 2A, COX-2 was
undetectable in normal mucosa samples. In-
creased COX-2 expression was detected in
41.7% of EGM specimens (Figure 2B and
C) and in 90% (9/10) of Barrett’s epithelium
Figure 1. Endoscopic appear-
ance of ectopic gastric mucosa
(arrow) with a smooth, regular
and velvety islet of columnar tis-
sue in the upper esophagus.
Table 1. Histological characteristics of ectopic gastric mu-
cosa.
N (%)
Epithelium type
Fundic 7 (58.3%)
Antral/fundic 5 (41.7%)
Chronic inflammatory changes
Absent 4 (33.3%)
Inactive 3 (25.0%)
Mild 5 (41.7%)
Helicobacter pylori (Giemsa)
Present 6 (50.0%)
Other histological findings
Intestinal metaplasia 2 (16.6%)
Table 2. Characteristics of ectopic gastric mucosa associ-
ated with Helicobacter pylori (HP) infection in 12 patients.
HP positive HP negative
Epithelium type
Fundic 2 3
Antral/fundic 4 3
Chronic inflammatory process
Absent 1 3
Inactive 0 3
Mild 5 0*
Intestinal metaplasia
Present 1 1
Absent 5 5
Helicobacter pylori (Giemsa)
Present 6 3
Absent 0 3
*P < 0.01 compared to HP-positive mucosa (chi-square test).
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specimens (Figure 2D).
The comparison of COX-2 expression
between normal mucosa and ectopic gastric
mucosa reached statistical significance (P =
0.04) as also did the comparison between
EGM and Barrett’s esophagus (P = 0.03).
Average COX-2 expression scores (21) in
EGM and Barrett’s esophagus were 2.1 (2.3)
and 6.1 (2.7), respectively (Figure 3).
We attempted to identify factors that could
contribute to COX-2 expression in EGM.
There was no difference related to age or
gender. The presence of endoscopic find-
ings of gastroesophageal reflux disease
(GERD) was not associated with COX-2
immunoexpression, nor was epithelium type,
presence of chronic inflammation, or H. py-
lori infection (Table 3).
Discussion
Heterotopic gastric mucosa is defined as
a salmon pink colored patch localized in the
upper esophagus and also designated as inlet
patch. The prevalence of EGM in our study
was 1.1%, consistent with published reports
(1-3). Symptoms occur in 6.2 to 20% of
cases, mainly globus sensation, hoarseness,
odynophagia, dysphagia, or oropharyngeal
burning (2).
The macroscopic and microscopic char-
acteristics of the inlet patches were similar to
those previously reported. Diameter ranged
from 2 to 50 mm, although in most cases it
was smaller than 10 mm (1-3,7). Presenta-
tion is usually as a single lesion (42 to 85%),
but occasionally two or more distinct patches
can be observed (1-3,7). In our study, most
cases presented a single patch (71.4%) and
average size was 6.5 mm (range 2 to 20 mm),
with 78.6% of lesions measuring 10 mm or
less.
Fundic type mucosa was more frequent
than antral fundic type mucosa (58.3 vs
41.7%) and chronic inflammation was found
in 66.7% of cases, consistent with previous
reports (1-3,7). Intestinal metaplasia was
Figure 2. Examples of cyclooxy-
genase-2 (COX-2) immunoreac-
tivity. A, No COX-2 expression
in the normal specimen (200X).
B, Immunohistochemical stain-
ing in ectopic gastric mucosa
(arrows; 200X), and C, detail of
the positive immunoexpression
in the same specimen (400X),
represented by a gray layer (ar-
rows). D, COX-2 immunoex-
pression in Barrett’s esophagus
metaplastic epithelium (200X),
demonstrated by a higher inten-
sity gray layer (arrows).
Figure 3. Box-plot showing the
average distribution of cyclooxy-
genase-2 (COX-2) Yamauchi et
al. (21) score in 30 normal speci-
mens, 12 ectopic gastric mucosa
(EGM) and 10 Barrett’s esopha-
gus. (Error bars are ± SD and
horizontal lines are medians).
The value obtained for normal
specimens was zero, since there
was no COX-2 expression in the
normal tissue.
Table 3. Comparison of various characteristics of ectopic gastric mucosa specimens
regarding cyclooxygenase-2 (COX-2) immunoexpression.
Characteristics COX-2 positive COX-2 negative
Gender
Male:female 4:1 4:3
Age (years)
Mean 38 56
Range 18-67 40-84
Associated endoscopic condition
Gastritis 1 (20%) 6 (85.7%)*
Duodenal ulcer 0 2 (28.6%)
Esophagitis 2 (40%) 1 (14.3%)
Hiatal hernia 1 (20%) 1 (14.3%)
Portal hypertension 1 (20%) 0
Epithelium type
Fundic 2 (40%) 5 (71.4%)
Antral/fundic 3 (60%) 2 (28.6%)
Chronic inflammatory changes
Absent 1 (20%) 3 (42.9%)
Inactive 3 (60%) 0
Mild 1 (20%) 4 (57.1%)
Helicobacter pylori
Present 1 (20%) 5 (71.4%)
Intestinal metaplasia 0 2 (28.6%)
Data are reported as number with percent in parentheses unless otherwise indicated.
P < 0.05 compared to COX-2-positive specimens (chi-square test).
A B
C D
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observed in 16.6% of patients, a slightly
higher prevalence than previously reported
(1-3).
EGM colonization by H. pylori has been
described in 5.3 to 56.5% of patients (1-4,7).
In this study, it was present in half the cases
and was closely related to the presence of
chronic inflammation (P = 0.01). We found
no association with H. pylori antral infec-
tion. The presence of the bacteria was not
correlated with mucosal type or with the
presence of metaplasia.
Barrett’s esophagus was not identified in
any patient and GERD endoscopic findings
did not correlate with the presence of an inlet
patch.
EGM has been considered to be an inci-
dental finding during upper endoscopy. How-
ever, some complications have been de-
scribed, such as dysphagia due to rings or
benign strictures (22,23), ulceration (24),
bleeding (25), esophago-tracheal fistulae
(26), or perforation (27).
EGM is considered to be embryologic
defect pathogenetically distinct from Bar-
rett’s esophagus. Contradictory data have
been published about the immunohistochemi-
cal profiles of these two entities. Similarities
have been demonstrated in the mucin profile
(5), cytokeratin 7 and 20 pattern (28), and
mucin core protein (28).
Adenocarcinomas developing on the
EGM of the cervical esophagus are extremely
rare and only few isolated cases have been
reported (8-10). COX-2 is over-expressed in
Barrett’s esophagus and is involved in the
sequence of events that lead to malignant
transformation (19). The main objective of
the present study was to determine COX-2
immunoexpression by the EGM and to com-
pare it with the expression observed in nor-
mal esophagogastric and Barrett’s esopha-
gus samples.
The potential involvement of COX-2 in
gastrointestinal carcinogenesis has been ex-
tensively discussed in the literature. Several
studies have confirmed COX-2 over-expres-
sion in colorectal cancer (11,21,29) gastric
adenocarcinoma (13,16,30) and esophageal
adenocarcinoma (19).
Experimental studies have demonstrated
that COX-2 inhibits cell apoptosis, increases
cell growth and promotes angiogenesis, con-
tributing to tumorigenesis and increasing
tumor invasiveness and metastatic potential
(13-18). In vitro studies have suggested that
COX-2 is able to suppress apoptosis and to
exacerbate tumorigenic risk (14,17). Cells
over-expressing COX-2 contain increased
amounts of anti-apoptotic protein bcl-2 (16).
Selective in vitro COX-2 inhibition has been
associated with significantly suppressed cell
growth (proliferation) and increased apop-
tosis in esophageal adenocarcinoma cell lines
(14,31).
Increased invasiveness has been attrib-
uted to the modulation of cell adhesion by
COX-2. The expression of adhesion pro-
teins is decreased in cells over-expressing
COX-2. These cell lines also have altered
adhesion to structural proteins. Both factors
seem to decrease cell adhesion and to in-
crease invasive potential (17). Another pos-
sible important mechanism is the activation
and formation of metalloproteinases 1 and 2
within cells expressing COX-2. These en-
zymes digest the collagen matrix of the base-
ment membrane, thus stimulating the inva-
sive and proliferative properties of tumor
cells (18).
In vitro studies have confirmed the anti-
proliferative and pro-apoptotic effects pro-
moted by selective inhibition of COX-2 in
Barrett’s adenocarcinoma and also in esoph-
ageal squamous carcinoma cell lines (14).
Buskens et al. (12) found negative or
only weak COX-2 expression in the squa-
mous epithelium of the esophagus. Lagorce
et al. (19) identified over-expression in
Barrett’s esophagus compared to normal
esophageal epithelium, unrelated to the de-
gree of dysplasia and suggested that increased
COX-2 expression plays an early role in the
process of neoplastic transformation of
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Barrett’s mucosa and may contribute to tu-
mor formation. COX-2 expression is corre-
lated with more aggressive clinicopathologi-
cal tumor features, especially metastatic po-
tential and poor prognosis (12).
We have detected high COX-2 expres-
sion in EGM. Immunoexpression of COX-2
was lower in EGM than in Barrett’s esopha-
gus specimens. Our results indicate a pro-
gressive over-expression of COX-2 from
normal esophageal and gastric mucosa to
EGM and Barrett’s esophagus.
COX-2 immunoexpression was not re-
lated to gender, age, epithelium type, pres-
ence of chronic inflammation or intestinal
metaplasia, H. pylori infection, or any of the
associated endoscopic findings.
In the present study, COX-2 expression
was not related to endoscopic GERD find-
ings (P = 0.22). We found no correlation
between H. pylori infection and COX-2 ex-
pression in EGM. To our knowledge, there
are no published data concerning COX-2
expression in heterotopic gastric mucosa.
Although the number of patients was
small, our results confirmed high COX-2
expression in heterotopic mucosa, which
could be interpreted as an eventual potential
of neoplastic transformation of a so-called
harmless mucosa.
Further studies are necessary to clarify
the real malignant potential of this ectopic
mucosa. Studies involving larger numbers
of patients and a long follow-up will be
necessary to confirm these results and to
define the procedure to be followed. How-
ever, as of now, it may be advisable to
perform a biopsy.
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